Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
Introduction: Interleukin-6 (IL-6) is the key cytokine in “cytokine release syndrome” and associated with the lung fibrosis. Tocilizumab (TCZ) reduces the negative effects of inflammation by blocking the binding of IL-6 to its receptor. Materials and Methods: This was a retrospective observational...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Turkish |
| Published: |
Galenos Yayinevi
2021-01-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | http://mjima.org/abstract.php?id=297 |